Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit 11 gene-mutated gastrointestinal stromal tumors

Figure 3 Kaplan-Meier curves of progression-free survival between dose-escalation group (Group A) and drug switch group (Group B). A: The Kaplan-Meier curves indicated that there was no significant difference in progression-free survival (PFS) between the dose-escalation group and drug-switch group in the low plasma concentration group (log-rank P = 0.66); B: The Kaplan-Meier curves indicated that the drug switch group had a longer overall survival than the dose-escalation group (log-rank P = 0.03).